We have 3 of 91 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Onpattro, the first FDA-approved RNAi therapy, is highlighted, Onpattro’s clinical development is highlighted, compares delivery platforms, discusses translational challenges, and emerging technologies that will guide the next generation of RNAi nanomedicines in personalized therapy are examined.
The developed system with remarkable wound healing potential was displayed, displaying chemical stability, improved aqueous solubility and wound area reduction in the present study.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
